Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials.

Full Abstract

Although levels of minimal residual disease (MRD) decrease below the detection limit in most adult patients with standard-risk acute lymphoblastic leukemia (ALL) after consolidation treatment, about 30% of these patients will ultimately relapse. To evaluate the power of MRD monitoring as an indicator of impending relapse, we prospectively analyzed postconsolidation samples of 105 patients enrolled in the German Multicenter ALL (GMALL) trial by real-time quantitative polymerase chain reaction (PCR) of clonal immune gene rearrangements. All patients were in hematologic remission, had completed first-year polychemotherapy, and tested MRD negative prior to study entry. Twenty-eight of 105 patients (27%) converted to MRD positivity thereafter, and 17 of 28 (61%) relapsed so far. Median time from molecular (MRD-positive) to clinical relapse was 9.5 months. In 15 of these patients, MRD within the quantitative range of PCR was measured in hematologic remission, and 13 of these patients (89%) relapsed after a median interval of 4.1 months. Of the 77 continuously MRD-negative patients, only 5 (6%) have relapsed. We conclude that conversion to MRD positivity during the early postconsolidation phase in adult standard-risk ALL patients is highly predictive of subsequent hematologic relapse. As a result of the study, as of spring 2006, salvage treatment in the ongoing GMALL trial is intended to be started at the time of recurrence of quantifiable MRD.

Learn Faster Today Improve your study skills

Author information

Author/s: Raff, Thorsten (T); Gökbuget, Nicola (N); Lüschen, Silke (S); Reutzel, Regina (R); Ritgen, Matthias (M); Irmer, Sebastian (S); Böttcher, Sebastian (S); Horst, Heinz-August (HA); Kneba, Michael (M); Hoelzer, Dieter (D); Brüggemann, Monika (M); GMALL Study Group;

Affiliation: Second Medical Department, University Schleswig-Holstein, Campus Kiel, Germany. t.raff(-atsign-)med2.uni-kiel.de

Journal and publication information

Publication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

Journal: Blood (Blood), published in United States. (Language: eng)

Reference: 2007-Feb; vol 109 (issue 3) : pp 910-5

Dates: Created 2007/01/24; Completed 2007/03/06; Revised 2007/11/15;

PMID: 17023577, status: MEDLINE (last retrieval date: 12/26/2008)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article (including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Adolescent
Adult
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Clinical Trials as Topic
Female
Follow-Up Studies
Gene Rearrangement
Humans
Male

Middle Aged
Molecular Diagnostic Techniques
Neoplasm, Residual - diagnosis; drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis; drug therapy
Predictive Value of Tests
Prospective Studies
Recurrence
Reverse Transcriptase Polymerase Chain Reaction
Salvage Therapy

These are the highest related articles currently in the database:

See 100+ related articles.